Market Research Reports and Industry Reports

Cervical Cancer - Pipeline Review, H2 2017

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Cervical Cancer - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Cervical Cancer - Pipeline Review, H2 2017, provides an overview of the Cervical Cancer (Oncology) pipeline landscape.

Cervical intraepithelial neoplasia (CIN), also known as cervical dysplasia is characterized by abnormal appearance of cells on the surface of the cervix. Cervical dysplasia usually occurs in women aging twenty five to thirty five. Most cases of cervical dysplasia are caused by human papilloma virus (HPV). Factors contributing to cervical dysplasia include using immunosuppressants and smoking. Signs and symptoms include genital warts, abnormal bleeding, spotting after intercourse, vaginal discharge and low back pain.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Cervical Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Cervical Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cervical Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Cervical Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 6, 34, 36, 47, 9 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 4, 4, 11 and 6 molecules, respectively.

Cervical Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Cervical Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Cervical Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cervical Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cervical Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Cervical Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cervical Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cervical Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction 7
Cervical Cancer - Overview 8
Cervical Cancer - Therapeutics Development 9
Cervical Cancer - Therapeutics Assessment 30
Cervical Cancer - Companies Involved in Therapeutics Development 44
Cervical Cancer - Drug Profiles 85
Cervical Cancer - Dormant Projects 640
Cervical Cancer - Discontinued Products 645
Cervical Cancer - Product Development Milestones 646
Appendix 657

List Of Tables

List of Tables
Number of Products under Development for Cervical Cancer, H2 2017 25
Number of Products under Development by Companies, H2 2017 27
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 28
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 29
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 30
Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017 31
Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017 32
Number of Products under Development by Universities/Institutes, H2 2017 33
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 35
Products under Development by Companies, H2 2017 36
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 37
Products under Development by Companies, H2 2017 (Contd..2), H2 2017 38
Products under Development by Companies, H2 2017 (Contd..3), H2 2017 39
Products under Development by Companies, H2 2017 (Contd..4), H2 2017 40
Products under Development by Companies, H2 2017 (Contd..5), H2 2017 41
Products under Development by Companies, H2 2017 (Contd..6), H2 2017 42
Products under Development by Companies, H2 2017 (Contd..7), H2 2017 43
Products under Development by Universities/Institutes, H2 2017 44
Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 45
Number of Products by Stage and Target, H2 2017 47
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 48
Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017 49
Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017 50
Number of Products by Stage and Mechanism of Action, H2 2017 52
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 53
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017 54
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017 55
Number of Products by Stage and Route of Administration, H2 2017 57
Number of Products by Stage and Molecule Type, H2 2017 59
Cervical Cancer - Pipeline by Abion Inc, H2 2017 60
Cervical Cancer - Pipeline by Abivax SA, H2 2017 60
Cervical Cancer - Pipeline by Admedus Ltd, H2 2017 61
Cervical Cancer - Pipeline by Advaxis Inc, H2 2017 61
Cervical Cancer - Pipeline by Advenchen Laboratories LLC, H2 2017 62
Cervical Cancer - Pipeline by Agenus Inc, H2 2017 62
Cervical Cancer - Pipeline by Amgen Inc, H2 2017 63
Cervical Cancer - Pipeline by AntiCancer Inc, H2 2017 63
Cervical Cancer - Pipeline by Antigen Express Inc, H2 2017 63
Cervical Cancer - Pipeline by Arbor Vita Corp, H2 2017 64
Cervical Cancer - Pipeline by ArQule Inc, H2 2017 64
Cervical Cancer - Pipeline by Asana BioSciences LLC, H2 2017 65
Cervical Cancer - Pipeline by AstraZeneca Plc, H2 2017 65
Cervical Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2017 66
Cervical Cancer - Pipeline by Bayer AG, H2 2017 66
Cervical Cancer - Pipeline by BeiGene Ltd, H2 2017 67
Cervical Cancer - Pipeline by Bioleaders Corp, H2 2017 67
Cervical Cancer - Pipeline by Biomics Biotechnologies Co Ltd, H2 2017 67
Cervical Cancer - Pipeline by Blirt SA, H2 2017 68
Cervical Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2017 68
Cervical Cancer - Pipeline by Bristol-Myers Squibb Co, H2 2017 69
Cervical Cancer - Pipeline by Cadila Healthcare Ltd, H2 2017 69
Cervical Cancer - Pipeline by Cancer Research Technology Ltd, H2 2017 69
Cervical Cancer - Pipeline by Celleron Therapeutics Ltd, H2 2017 70
Cervical Cancer - Pipeline by Coherus BioSciences Inc, H2 2017 70
Cervical Cancer - Pipeline by Critical Outcome Technologies Inc, H2 2017 71
Cervical Cancer - Pipeline by Cytori Therapeutics Inc, H2 2017 71
Cervical Cancer - Pipeline by CZ BioMed Corp, H2 2017 72
Cervical Cancer - Pipeline by DelMar Pharmaceuticals Inc, H2 2017 72
Cervical Cancer - Pipeline by Dr. Reddys Laboratories Ltd, H2 2017 73
Cervical Cancer - Pipeline by Eisai Co Ltd, H2 2017 73
Cervical Cancer - Pipeline by Etubics Corp, H2 2017 73
Cervical Cancer - Pipeline by Eureka Therapeutics Inc, H2 2017 74
Cervical Cancer - Pipeline by EyeGene Inc, H2 2017 74
Cervical Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 75
Cervical Cancer - Pipeline by Formune SL, H2 2017 75
Cervical Cancer - Pipeline by GamaMabs Pharma SA, H2 2017 76
Cervical Cancer - Pipeline by Gene Techno Science Co Ltd, H2 2017 76
Cervical Cancer - Pipeline by Genentech Inc, H2 2017 77
Cervical Cancer - Pipeline by Genmab A/S, H2 2017 77
Cervical Cancer - Pipeline by Genor BioPharma Co Ltd, H2 2017 77
Cervical Cancer - Pipeline by GlaxoSmithKline Plc, H2 2017 78
Cervical Cancer - Pipeline by Glycostem Therapeutics BV, H2 2017 78
Cervical Cancer - Pipeline by Glycotope GmbH, H2 2017 79
Cervical Cancer - Pipeline by Gradalis Inc, H2 2017 79
Cervical Cancer - Pipeline by Immunomedics Inc, H2 2017 80
Cervical Cancer - Pipeline by Immunovaccine Inc, H2 2017 80
Cervical Cancer - Pipeline by Innate Pharma SA, H2 2017 81
Cervical Cancer - Pipeline by Innovation Pharmaceuticals Inc, H2 2017 81
Cervical Cancer - Pipeline by Iovance Biotherapeutics Inc, H2 2017 81
Cervical Cancer - Pipeline by ISA Pharmaceuticals BV, H2 2017 82
Cervical Cancer - Pipeline by Johnson & Johnson, H2 2017 82
Cervical Cancer - Pipeline by Juno Therapeutics Inc, H2 2017 83
Cervical Cancer - Pipeline by Kaketsuken, H2 2017 83
Cervical Cancer - Pipeline by Karyopharm Therapeutics Inc, H2 2017 84
Cervical Cancer - Pipeline by Kite Pharma Inc, H2 2017 84
Cervical Cancer - Pipeline by LondonPharma Ltd, H2 2017 85
Cervical Cancer - Pipeline by Mabion SA, H2 2017 85
Cervical Cancer - Pipeline by MedImmune LLC, H2 2017 86
Cervical Cancer - Pipeline by Merck & Co Inc, H2 2017 86
Cervical Cancer - Pipeline by Merck KGaA, H2 2017 87
Cervical Cancer - Pipeline by Mycenax Biotech Inc, H2 2017 87
Cervical Cancer - Pipeline by Nektar Therapeutics, H2 2017 88
Cervical Cancer - Pipeline by NeoImmuneTech Inc, H2 2017 88
Cervical Cancer - Pipeline by Ology Bioservices Inc, H2 2017 88
Cervical Cancer - Pipeline by Oncobiologics Inc, H2 2017 89
Cervical Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017 90
Cervical Cancer - Pipeline by Oryx GmbH & Co KG, H2 2017 90
Cervical Cancer - Pipeline by PDS Biotechnology Corp, H2 2017 90
Cervical Cancer - Pipeline by Pfizer Inc, H2 2017 91
Cervical Cancer - Pipeline by Pharma Mar SA, H2 2017 91
Cervical Cancer - Pipeline by Psicofarma SA de CV, H2 2017 92
Cervical Cancer - Pipeline by Puma Biotechnology Inc, H2 2017 92
Cervical Cancer - Pipeline by Regeneron Pharmaceuticals Inc, H2 2017 93
Cervical Cancer - Pipeline by Rexahn Pharmaceuticals Inc, H2 2017 93
Cervical Cancer - Pipeline by Richter Gedeon Nyrt, H2 2017 94
Cervical Cancer - Pipeline by Samyang Holdings Corp, H2 2017 94
Cervical Cancer - Pipeline by Sanofi, H2 2017 95
Cervical Cancer - Pipeline by Seattle Genetics Inc, H2 2017 95
Cervical Cancer - Pipeline by Selecta Biosciences Inc, H2 2017 96
Cervical Cancer - Pipeline by Shantha Biotechnics Pvt Ltd, H2 2017 96
Cervical Cancer - Pipeline by Sirnaomics Inc, H2 2017 96
Cervical Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017 97
Cervical Cancer - Pipeline by Tessa Therapeutics Pte Ltd, H2 2017 97
Cervical Cancer - Pipeline by Theralase Technologies Inc, H2 2017 98
Cervical Cancer - Pipeline by Theravectys SA, H2 2017 98
Cervical Cancer - Pipeline by THEVAX Genetics Vaccine USA Inc, H2 2017 98
Cervical Cancer - Pipeline by UbiVac LLC, H2 2017 99
Cervical Cancer - Pipeline by Vectorite Biomedica Inc, H2 2017 99
Cervical Cancer - Pipeline by VLPbio, H2 2017 99
Cervical Cancer - Pipeline by Wellstat Biologics Corp, H2 2017 100
Cervical Cancer - Pipeline by Zeria Pharmaceutical Co Ltd, H2 2017 100
Cervical Cancer - Dormant Projects, H2 2017 656
Cervical Cancer - Dormant Projects, H2 2017 (Contd..1), H2 2017 657
Cervical Cancer - Dormant Projects, H2 2017 (Contd..2), H2 2017 658
Cervical Cancer - Dormant Projects, H2 2017 (Contd..3), H2 2017 659
Cervical Cancer - Dormant Projects, H2 2017 (Contd..4), H2 2017 660
Cervical Cancer - Discontinued Products, H2 2017 661

Global Cervical Anterior Approach Device Package Market Professional Survey Report 2017

This report studies Cervical Anterior Approach Device Package in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in

USD 3500View Report

Cervical Cancer - Pipeline Review, H2 2017

Cervical Cancer - Pipeline Review, H2 2017Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Cervical Cancer - Pipeline Review, H2 2017, provides an overview of the Cervical Cancer

USD 2000View Report

EpiCast Report: Prostate Cancer - Epidemiology Forecast to 2026

EpiCast Report: Prostate Cancer - Epidemiology Forecast to 2026Prostate cancer is a malignancy in the prostate gland, which is located below the bladder and in front of the rectum in

USD 3995View Report

Bladder Cancer - Pipeline Review, H2 2017

Bladder Cancer - Pipeline Review, H2 2017Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Bladder Cancer - Pipeline Review, H2 2017, provides an overview of the Bladder Cancer

USD 2000View Report

Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)


+91 9987 2952 42

CHOOSE FORMAT

  • PDF    USD 2000
  • Site Licence    USD 4000
  • Enterprise Wide Licence    USD 6000
$ 2000

Reports Details

Published Date : Nov 2017
No. of Pages :674
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube